Eton Pharmaceuticals Inc. (ETON) Reports Q1 EPS of $0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eton Pharmaceuticals Reports Record Revenue and Earnings
May 13, 2021 4:05 PM EDTFirst quarter 2021 revenue of $11.9 millionFirst quarter 2021 operating earnings of $5.4 million; EPS of $0.19Eton now has three commercial, revenue-generating products
DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.
We are proud to report record revenue and the first profitable quarter in Etons history, said Sean Brynjelsen, CEO of Eton Pharmaceuticals. We have... More
